A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Astellas logo

Astellas

Status

Completed

Conditions

Invasive Fungal Infections

Treatments

Drug: Micafungin

Study type

Observational

Funder types

Industry

Identifiers

NCT02678598
9463-MA-3003

Details and patient eligibility

About

The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.

Enrollment

2,555 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who received Micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy
  • Patients received Micafungin treatment at least 1 dose

Exclusion criteria

  • Patients received Micafungin treatment combined with other antifungal drugs at the same time
  • Neither efficacy or safety can be evaluated because of missing data, confused record

Trial design

2,555 participants in 1 patient group

Micafungin group
Treatment:
Drug: Micafungin

Trial contacts and locations

17

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems